We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

81 hedge funds and large institutions have $57.2M invested in CytomX Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $52.6M → $57.2M (+$4.61M)

4% more call options, than puts

Call options by funds: $56K | Put options by funds: $54K

0.57% less ownership

Funds ownership: 55.03% → 54.45% (-0.57%)

5% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 21

4% less funds holding

Funds holding: 84 → 81 (-3)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

Holders
81
Holders Change
-3
Holders Change %
-3.57%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
20
Reduced
21
Closed
16
Calls
$56K
Puts
$54K
Net Calls
+$2K
Net Calls Change
-$28K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.76M
2
Citadel Advisors
Citadel Advisors
Florida
+$605K
3
Two Sigma Investments
Two Sigma Investments
New York
+$566K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$190K
5
CM
CM Management
Florida
+$111K

Top Sellers

Rank Fund Capital Flow
1
PIM
Platinum Investment Management
Australia
-$878K
2
BlackRock
BlackRock
New York
-$739K
3
Renaissance Technologies
Renaissance Technologies
New York
-$688K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$640K
5
E
Ergoteles
New York
-$405K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$10.6M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.34M +$70.7K +47,760 +1%
TCM
3
Tang Capital Management
California
$5.62M +$15.5K +10,445 +0.3%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$4.24M – – –
RCMNY
5
Rubric Capital Management (New York)
New York
$3.85M – – –
Millennium Management
6
Millennium Management
New York
$2.75M +$1.76M +1,187,298 +223%
Renaissance Technologies
7
Renaissance Technologies
New York
$2.15M -$688K -464,826 -26%
BlackRock
8
BlackRock
New York
$2.08M -$739K -499,362 -28%
LCM
9
Laurion Capital Management
New York
$2.03M – – –
Assenagon Asset Management
10
Assenagon Asset Management
Luxembourg
$1.46M -$223K -150,492 -14%
Two Sigma Investments
11
Two Sigma Investments
New York
$1.19M +$566K +382,763 +107%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$1.15M +$22.3K +15,074 +2%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$1.06M -$640K -432,426 -40%
PIM
14
Platinum Investment Management
Australia
$1.02M -$878K -593,747 -48%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$989K +$190K +128,744 +26%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$964K +$23.1K +15,624 +3%
NM
17
Newtyn Management
New York
$912K -$340K -230,000 -29%
OMC
18
Oasis Management Company
Cayman Islands
$865K – – –
Two Sigma Advisers
19
Two Sigma Advisers
New York
$840K -$3.7K -2,500 -0.5%
Citadel Advisors
20
Citadel Advisors
Florida
$733K +$605K +408,759 +832%
TI
21
Tidal Investments
Wisconsin
$553K +$51.2K +34,590 +11%
FAM
22
Formidable Asset Management
Ohio
$509K +$10.2K +6,918 +2%
TC
23
Tejara Capital
United Kingdom
$378K +$349K +236,050 New
State Street
24
State Street
Massachusetts
$358K – – –
CC
25
Clearline Capital
New York
$315K – – –
1
2 3 4

CTMX Hedge Fund Activity: Q4 2022 in Review

81 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2022, worth a combined $57.2M — up 8.8% from $52.6M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTMX and 13 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 20 added.

The largest buyer was Millennium Management, adding an estimated $1.76M. The largest seller was Platinum Investment Management, cutting an estimated $878K.

  • 81 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2022, down from 84 in Q3 2022.
  • Funds reported $57.2M of CytomX Therapeutics stock for Q4 2022, up 8.8% quarter-over-quarter.
  • 13 funds opened new CytomX Therapeutics positions in Q4 2022 and 16 closed out, a net change of -3 holders.
  • The largest CytomX Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $1.76M added.
  • The largest CytomX Therapeutics seller in Q4 2022 was Platinum Investment Management, an estimated $878K sold.

Based on aggregated 13F filings for Q4 2022.